Do you want to read an article? Please log in or register.
Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial
Cardiovascular Risk and Diseases
Related content
Heart, Artery and Coronary Diseases
Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial
J Am Coll Cardiol.
Low Wang CC, Blomster JI, Heizer G, Berger JS, Baumgartner I, Fowkes FGR, Held P, Katona BG, Norgren L, Jones WS, Lopes RD, Olin JW, Rockhold FW, Mahaffey KW, Patel MR, Hiatt WR; EUCLID Trial Executive Committee and Investigators
doi: 10.1016/j.jacc.
RECOMMENDED
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
doi: 10.1016/S0140-
Heart, Artery and Coronary DiseasesMyocardial Infarction
Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial
JAMA Cardiol.
Olivier CB, Mulder H, Hiatt WR, Jones WS, Fowkes FGR, Rockhold FW, Berger JS, Baumgartner I, Held P, Katona BG, Norgren L, Blomster J, Patel MR, Mahaffey KW
doi: 10.1001/jamacardio.
Heart Failure
Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial
J Am Heart Assoc.
Sharma A, Vaduganathan M, Ferreira JP, Liu Y, Bakris GL, Cannon CP, White WB, Zannad F
doi: 10.1161/JAHA.119.012797.
RECOMMENDED
Heart, Artery and Coronary Diseases
Dapagliflozin and Cardiac, Kidney and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Circulation.
Bonaca MP, Wiviott SD, Zelniker TA, Mosenzon O, Bhatt DL, Leiter LA, McGuire DK, Goodrich EL, Furtado RHM, Wilding JPH, Cahn A, Gause-Nilsson IAM, Johanson P, Fredriksson M, Johansson PA, Langkilde AM, Raz I, Sabatine MS
doi: 10.1161/CIRCULATIONAHA.119.044775.
RECOMMENDED
Cardiovascular Risk and Diseases
Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
J Am Heart Assoc.
Arnott C, Li Q, Kang A, Neuen BL, Bompoint S, Lam CSP, Rodgers A, Mahaffey KW, Cannon CP, Perkovic V, Jardine MJ, Neal B
doi: 10.1161/JAHA.119.014908.
Cardiac Arrest or DeathMyocardial InfarctionThrombosis and StrokeTherapy and Intervention
Glycemic Control Status After Percutaneous Coronary Intervention and Long-Term Clinical Outcomes in Patients With Type 2 Diabetes Mellitus
Circ Cardiovasc Interv.
Hwang JK, Lee SH, Song YB, Ahn J, Carriere K, Jang MJ, Park TK, Choi SH, Yang JH, Choi JH, Lee SH, Gwon HC, Hahn JY
doi: 10.1161/
Cardiovascular Risk and Diseases
Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials
Eur Heart J.
Marsico F, Paolillo S, Gargiulo P, Bruzzese D, Dell'Aversana S, Esposito I, Renga F, Esposito L, Marciano C, Dellegrottaglie S, Iesu I, Perrone Filardi P
doi: 10.1093/eurheartj/ehaa082.
Heart, Artery and Coronary Diseases
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial
Lancet.
Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, Held C, Andersson M, Himmelmann A, Ridderstråle W, Chen J, Song Y, Diaz R, Goto S, James SK, Ray KK, Parkhomenko AN, Kosiborod MN, McGuire DK, Harrington RA, THEMIS Steering Committee and Investigators.
doi: 10.1016/S0140-6736(19)31887-2.